期刊
INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
卷 221, 期 -, 页码 334-345出版社
ELSEVIER
DOI: 10.1016/j.ijbiomac.2022.08.185
关键词
Amyloid fibrils; Curcumin; Molecularly imprinting; Amyloid inhibitors
资金
- Key Research & Development Program Foundation of Shaanxi [2022GY-198]
This study developed a curcumin lysozyme-imprinted nanosphere (CUR-MIMS) that effectively inhibited the aggregation of lysozyme and showed good biocompatibility, demonstrating its potential as a therapeutic platform for amyloidosis.
Some natural variants of human lysozyme are associated with systemic non-neurological amyloidosis that leads to amyloid protein fibril deposition in different tissues. Inhibition of amyloid fibrillation by nanomaterials is considered to be an effective approach to treating amyloidosis. Here, we prepared a targeted, highly loaded curcumin lysozyme-imprinted nanosphere (CUR-MIMS) that could effectively inhibit the aggregation of lyso-zyme with lysozyme adsorption capacity of 193.57 mg g-1 and the imprinting factor (IF) of 3.72. CUR-MIMS could bind to lysozyme through hydrophobic interactions and effectively reduce the hydrophobicity of the total solvent-exposed surface in lysozyme fibrillation, thus reducing the self-assembly process triggered by hy-drophobic interactions. Thioflavin T (ThT) analysis demonstrated that CUR-MIMS inhibited the aggregation of amyloid fibrils in a dose-dependent manner (inhibition efficiency of 56.07 %). Circular dichroism (CD) spectrum further illustrated that CUR-MIMS could significantly inhibit the transition of lysozyme from alpha-helix structure to beta-sheet. More importantly, biological experiments proved the good biocompatibility of CUR-MIMS, which indicated the potential of our system as a future therapeutic platform for amyloidosis.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据